Skip to main content
Clinical Trials/NCT04198961
NCT04198961
Completed
N/A

An Electronic Chart Intervention to Improve Safety for Patients on Chronic Opioid Therapy

Stanford University1 site in 1 country43 target enrollmentJune 17, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Chronic Opioid Therapy
Sponsor
Stanford University
Enrollment
43
Locations
1
Primary Endpoint
Change in the number of patients who receives naloxone prescription
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This pilot study will attempt to apply an electronic chart intervention to improve safety for patients on chronic opioid medications.

Registry
clinicaltrials.gov
Start Date
June 17, 2020
End Date
June 17, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Huiqiong Deng

Clinical Assistant Professor

Stanford University

Eligibility Criteria

Inclusion Criteria

  • Patients prescribed long-term opioid therapy of doses greater than 90 morphine equivalent daily dose (MEDD)

Exclusion Criteria

  • Patients prescribed short-term opioid medications for acute pain (less than a 90-day supply over the past 120 days), sublingual buprenorphine, methadone maintenance for opioid use disorder or with oncology or palliative care diagnoses will be excluded.

Outcomes

Primary Outcomes

Change in the number of patients who receives naloxone prescription

Time Frame: baseline, 1, 3- and 6-months and 12 months

Change in the number of patients who receives naloxone prescription

change of number of documentation about safety discussions

Time Frame: baseline, 1, 3- and 6-months and 12 months

change of number of documentation about safety discussions

change of number of order for urine toxicology screening

Time Frame: baseline, 1, 3- and 6-months and 12 months

change of number of order for urine toxicology screening

change of number of documentation of prescription drug monitoring program (CURES) results

Time Frame: baseline, 1, 3- and 6-months and 12 months

change of number of documentation of prescription drug monitoring program (CURES) results

change of number of signed opioid informed consent forms

Time Frame: baseline, 1, 3- and 6-months and 12 months

change of number of signed opioid informed consent forms

Secondary Outcomes

  • Change in number of patients on long-term high risk doses of opioid pain medications(baseline, 1, 3- and 6-months and 12 months)

Study Sites (1)

Loading locations...

Similar Trials